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1. Introduction 
Stress urinary incontinence (SUI) is defined as the complaint of involuntary leakage of urine 
on exertion or on sneezing or coughing (Abrams et al, 2002). Female SUI is a common 
distressing health problem, affecting large number of women worldwide, with prevalence 
rates ranging from 12.8% to 46.0% (Botlero et al, 2008). SUI is considered the most common 
type of urinary incontinence among women and presents about 50 % of these populations, 
while mixed urinary incontinence presents 36 % and only 14 % are due to urge urinary 
incontinence (Hannestad et al, 2000). SUI has a negative impact on women quality of life 
specially their social, physical, occupational, psychological, and sexual aspects of life. 
SUI arises when the bladder pressure exceeds the urethral pressure, in the setting of sudden 
increases of intra-abdominal pressure (coughing, sneezing …etc). Most researchers now 
identify two main etiologic mechanisms for the development of SUI: urethral hypermobility 
due to loss of urethral support - the hammock-like supportive layer described by DeLancey 
(DeLancey, 1994 ), and intrinsic sphincter deficiency (ISD), with most patients having 
elements of both disorders (Table 1). 
There are several options for treatment of female SUI. Conservative treatment (pelvic floor 
muscle exercise) is usually advocated as a 1st line therapy since it carries minimal risks and 
studies have shown up to 70% improvement in symptoms of SUI following appropriately 
performed pelvic floor exercise (Price, Dawood and Jackson, 2010). Conservative 
management strategies include: 
1. Life style changes (weight reduction, smoking cessation, ↓ fluid intake, treatment of 
constipation …. etc). 
2. Pelvic floor muscle training ± biofeedback. 
3. Vaginal cones and electrical stimulation. 
Regarding pharmacotherapy, no drug till now has been approved to be used by the Food 
and Drug Administration (FDA) for the treatment of female SUI. Duloxetine is a serotonin–
norepinephrine reuptake inhibitor (SNRI) has been investigated, it can significantly improve 
the quality of life of patients with SUI, but it is unclear whether or not benefits are 
sustainable in addition it has a common side-effects (Mariappan et al, 2007). 
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1- Bladder neck/urethral hypermobility 
(due to loss of urethral support): 
 
- Vaginal delivery. 
- Aging. 
- Estrogen deficiency. 
- Connective tissue disorders. 
2- Intrinsic sphincter deficiency (ISD): - Multiple anti-incontinence 
procedures 
- Radical pelvic surgery 
- Radiation 
- Menopause 
- Urogenital atrophy 
3- Other risk factors: - Chronic  in intra-abdominal 
pressure. 
- Constipation. 
- Smoking. 
- Physical inactivity. 
- Genetic predisposition. 
Table 1. Show various etiological factors involved in the pathophysiology of SUI. 
Surgical treatment for SUI should be undertaken for women with SUI who have failed 
conservative treatment strategies or if the patient wants definitive treatment from the start.  
Over the past years, many surgical procedures have been used for the treatment of female 
SUI with varying degrees of success. Recently, a number of new minimally invasive surgical 
techniques have been developed for treatment of female SUI that aimed to decrease the 
morbidity, improved safety and improvement of the surgical outcomes, while maintaining 
the efficacy of traditional open incontinence surgery. The Tension free vaginal tape (TVT) 
procedure was first described and evaluated by Ulmsten et al in Sweden in 1996 (Ulmsten et 
al, 1996), then the Transobturator tape (TOT) procedure was developed in 2001 by DeLorme 
to avoid the retropubic space (DeLorme E, 2001). Midurethral slings (TVT and TOT) have 
the following advantages:  
1. The ability to be performed under local anaesthesia in patients who are unfit for major 
surgery.  
2. Better for young aged women due to better cosmetic appearance since there is now 
open wound such the old traditional surgical methods.  
3. Lower costs, shorter hospital stay, early recovery time and less postoperative pain. 
Further improvement in surgical procedures towards less invasive sling technique has led 
to the innovation of a mini-sling e.g. TVT Secur system, which is a surgical device 
requiring only a single suburethral incision to be inserted (Neuman and Shaare-Zedek, 
2007). Mini-slings have the following advantages over the ordinary midurethral slings 
(TVT and TOT):  
1. The complications associated with suprapubic and groin incisions will be eliminated.  
2. Cystoscopy will not be necessary.  
3. Operative time will be shorter than with other midurethral sling techniques. 
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2. Midurethral slings for SUI treatment 
2.1 Surgical principle of midurethral slings  
Petros and Ulmsten proposed the integral or midurethral theory of the female pelvic floor 
and urethral closure mechanism (Petros and Ulmsten, 1993), which has been the basis upon 
which many of the newer treatments for SUI have been developed. The idea that a loss of 
mid-urethral support is a causative factor in female SUI led to the use of synthetic 
midurethral tapes which became popular because of ease of placement and excellent 
outcomes. After their introduction by Ulmsten and Delorme, TVT and TOT gained a great 
popularity and rapid widespread and become now the gold standard treatment minimally 
invasive treatment of female SUI. Both techniques (TVT and TOT) aimed to recreating 
urethral support using a polypropylene mesh placed at midurethral without tension to 
create an artificial collagenous neoligament, using the foreign body reaction induced by the 
host defense mechanism. TVT acts as a pubourethral neoligament anchored suprapubically, 
which tightens around the urethra in the setting of increased intra-abdominal pressure. TOT 
had the following advantage over TVT by avoiding the blind trocar passage in the 
retropubic space by passing the trocar through the obturator muscles and membrane, thus 
decreasing the risk of major bladder, bowel perforation and vascular injury also decreasing 
the need for cystoscopy use after tape placement (figure 1 and 2). 
 
Fig. 1. TVT in position (Morley and Nethercliffe, 2005). 
 
Fig. 2. TOT in position (De Leval, 2003). 
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2.2 Clinical results of midurethral slings 
2.2.1 TVT surgical outcomes  
TVT has undergone the most rigorous testing all over the years, and now it is considered the 
gold standard treatment option for female SUI. To date it is estimated that more than 1 
million cases have been performed worldwide (Deng et al, 2007). There are now many 
prospective studies in literature with a long-term follow-up showing great success of TVT 
for the treatment of female SUI with cure rate > 80 % as seen in (table 2) denoting the long 
term durability of this procedure. In 2008, Nilsson et al reported the longest follow-up (11 
years) of TVT operation and demonstrated that (90% objective cure rate) of women treated 
without any significant late-onset adverse effects (Nilsson et al, 2008). In another study with 
follow-up for 10 years. TVT showed satisfactory objective (84%) and subjective (57%) cure 
rates with (23%) improvement (Aigmueller et al, 2011). 
 
Author Number of 
patients 
Patient group Duration of 
follow-up 
(years) 
Treatment outcomes 
(subjective/objective) 
% cured 
Villet et al, 2002 124 SUI 32.5 months 88.7% 
Rezapour et al, 
2001a 
34 Recurrent SUI 4 82% 
Rezapour et al, 
2001b 
80 Mixed urinary 
incontinence 
4 85% 
Rezapour et al, 
2001c 
49 SUI due to 
(ISD) 
4 74% 
Deffieux et al, 
2007 
51 SUI 6.9 80% 
Nilsson et al, 
2004 
90 SUI 7 81.3% 
Table 2. Long term results of TVT. 
TVT has replaced the old gold standard Burch colposuspension. In a randomized control 
trial (RCT) conducted by Ward and Hilton who compared TVT with the open 
colposuspension on they reported equal efficacy with subjective cure rate 81% and 80% in 
TVT and Burch group respectively. The duration of hospitalization, operative time and the 
time taken to return to normal activity seem to be shorter in the TVT group. The authors 
concluded that the TVT procedure is as effective as the Burch colposuspension in 
urodynamically proven patients with SUI at a 2-year follow-up (Ward and Hilton, 2004). 
The same authors have published their 5-year out comes in this study where they reported 
subjective cure in 81% in the TVT group and 90% in the colposuspension group. They stated 
that the effect of both procedures on cure and improvement in quality of life has been 
maintained for long time (Ward and Hilton, 2008). 
2.2.2 TOT surgical outcomes  
Short-term data regarding the efficacy of the TOT suggest that this procedure perform as 
well as the TVT and may perhaps cause fewer complications. TOT has shown to be of equal 
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efficacy to TVT with cure rate > 80% (table 3), however, still long-term studies have yet to be 
done to evaluate the effectiveness and durability of the TOT procedure. 
 
Author Number of 
patients 
Patient group Duration of 
follow-up 
Treatment 
outcomes 
(% cured) 
Cindolo et al, 
2004 
80 SUI with urethral 
hypermobility 
4 months 92 
Grise et al, 2006 206 SUI Mean 
(16 months) 
79.1 
Giberti et al, 
2007 
108 SUI due to 
urethral 
hypermobility 
2 years 80 
Roumeguere et 
al, 2005 
120 Urodynamic SUI 1 year 80 
Waltregny et al, 
2008 
91 SUI 3 year 88 
Liapis, Bakas 
and Creatsas, 
2010 
74 (32 TVT-O and 
41 TVT-O + ant. 
Colporrhaphy 
SUI and 
Cystocele 
4 year 82.4 and 80.5 % 
respectively 
Table 3. Results of TOT. 
2.2.3 TVT versus TOT outcomes  
TVT and TOT since their introduction in the treatment of female SUI have gained a great 
popularity and wide spread use in a large number of studies. Both techniques showed 
nearly equal efficacy with more than 80% cure rate in the majority of studies as mentioned 
before (Table 2, table 3). Novara et al, in a large systematic review and meta-analysis 
showed that patients treated with TVT had slightly higher objective cure rates (OR: 0.8;CI: 
0.65–0.99; p = 0.04) than those treated with TOT; however, subjective cure rates were similar 
in both technique (Novara et al, 2010). In a long term follow-up after 5 years both TVT and 
TVT-O procedures were safe, with equivalent results (72.9% and 71% of patients objectively 
cured after TVT-O and TVT, respectively) (Angioli et al, 2010). 
2.3 Material used for midurethral slings  
Over the past years there was a great evolution in the use of biological and synthetic 
materials in the treatment of different reconstructive pelvic surgery e.g. SUI and pelvic 
organ prolapse (POP) in an effort to improve surgical outcomes. However, the potential 
benefits of using grafts need to be carefully balanced against the risks of using foreign 
materials to the patient’s body. Amid in 1997 published a classification for synthetic mesh 
used in abdominal hernia surgery based on the pore size (macroporous, microporous, 
submicro-porous) and fiber type (monofilaments or multifilament) of the synthetic mesh 
(Amid, 1997). Synthetic grafts may be non-absorbable, absorbable, or a mixture of the two. 
The non-absorbable polypropylene mesh is the most common type used in reconstructive 
pelvic surgery. Synthetic tapes available in the market for urogynecological practice see 
(table 4). 
www.intechopen.com
 
Urinary Incontinence 
 
296 
The pore size and interstices distance between the fibers (figure 3) are important mesh 
characteristics that determine whether host inflammatory cell and fibroblasts can penetrate 
the mesh or not. The ideal synthetic tapes used for the treatment of SUI should have the 
following characters: made of polypropylene, low weight, macroporous, monofilament 
mesh, with an elasticity between 20 and 35%, as these tapes have a lower incidence of 
infection and tissue erosion (Rosch et al, 2004; Deprest et al, 2006). 
 
Pore size classification Component Trade name Fibre type 
Type I: Totally 
macroporous  
(pore size of >75 μm) 
Polypropylene 
 
 
 
Polypropylene/ 
Polyglactin 910 
Polyglactin 910 
Prolene, Gynemesh, 
Gynemesh PS 
(Ethicon) 
Marlex, Pelvitex a 
(Bard) 
Surgipro b SPMM 
(Tyco) 
Vypro (Ethicon) 
 
Vicryl (Ethicon) 
Monofilament 
 
Monofilament 
Monofilament 
Mono-
multifilament 
 
multifilament 
Type II: Totally 
microporous  
(pore size of <10 μm) 
Expanded PTFE Gore-Tex (Gore) multifilament 
Type III: Micro or 
macro-micro 
Polyethylene 
PTFE 
Braided 
polypropylene 
Braided 
polypropylene–
open weave 
Perforated 
Expanded PTFE 
Mersilene (Ethicon) 
Teflon (Gore) 
Surgipro b SPM 
(Tyco) 
Surgipro b SPMW 
(Tyco) 
 
Mycro-mesh (Gore) 
multifilament 
multifilament 
multifilament 
multifilament 
 
multifilament 
Type IV: Submicronic 
pore size  
(pore size of <1 μm) 
Polypropylene 
sheet 
Cellgard Monofilament 
PTFE: Polytetrafluoroethylene 
a Collagen coated macroporous polypropylene materials. 
b Several kinds of Surgipro (Tyco) materials are marketed under the same name and have different 
constructs. 
Table 4. Classification and characteristics of synthetic implant materials marketed for 
urogynecologic indications (Deprest et al, 2006). 
Type I macroporous mesh with (pore size >75 μm) allowing easier penetration of 
inflammatory cells such as leukocytes (9–15 μm), macrophages (16–20 μm), fibroblast and 
blood vessels into the graft to phagocytose bacteria (<1 μm) lowering the risk of infection, in 
addition host tissue in growth and incorporation is promoted resulting in good support. On 
the other hand, multifilament meshes have interstices that are <10 μm and bacteria (<1 μm) 
can replicate within these interstices. However, access to macrophages and ability to fight 
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bacterial colonisation within the interstices is impaired (Winters et al, 2006). Monofilament 
mesh does not have small interstices and the risk of mesh infection and erosion is reduced 
with its use.  
 
Fig. 3. Terminology used to classify synthetic implants. Magnified view of a part of a 
polypropylene tape as used for TVT procedure (Gynaecare, Johnson and Johnson) with 
identification of filament type, interstitium, and pore size (Deprest et al, 2006). 
Biological implants have many sources; they may be an autologous graft (derived from the 
patient’s own body tissue), allograft (derived from post-mortem tissue banks) or xenograft 
(derived from animals) (Dwyer, 2006). Types of biologic implants available in the market 
that can be used in urogynecology practice (table 5): 
 
Biological types Component Trade name 
Autologous grafts Rectus fascia 
Fascia lata 
Vaginal mucosa 
 
Allografts Fascia lata 
Dura mater 
 
Lyodura 
Xenografts Porcine non-cross-linked small intestine 
submucosal collagen 
Porcine non cross-linked dermal collagen 
Porcine dermal cross-linked collagen 
 
Fetal bovine skin derived collagen scaffold 
 
Bovine non-cross-linked pericardium 
Surgisis (Cook) 
 
InteXen (AMS) 
Pelvicol, Pelvisoft, 
Pelvilace (Bard) 
Xenform (Boston 
Scientific) 
Veritas (Synovis) 
Table 5. Classification of biologic implant materials marketed for urogynecologic indications 
(Deprest et al, 2006). 
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2.4 Complications of synthetic midurethral slings  
Although midurethral slings are minimally invasive procedures with high efficacy, however 
they result in bothersome complications which should not be minimized. The reported 
complication rates for midurethral slings ranged from 4.3% to 75.1% for TVT and 10.5% to 
31.3% for TOT (Daneshgari et al, 2008). Awareness of these complications should encourage 
improvements in patient counseling as well as further investigation of the underlying 
mechanisms. Summary of the complications of midurethral sling procedures (table 6): 
 
a) Intraoperative complications: - Major: Vascular lesions. 
 Nerve injuries. 
 Gut lesions. 
- Minor: Bladder injury. 
 Urethral injury. 
b) Early postoperative complications: - Retropubic haematoma. 
- Blood loss > 200 ml. 
- Urinary tract infections. 
- Spondylitis. 
c) Late postoperative complications: - Transient urinary retention. 
- Permanent urinary retention. 
- Groin and thigh pain. 
- Genitourinary erosion. 
- De novo urgency. 
- Urethral obstruction. 
- Dyspareunia. 
Table 6. Summary of the complications of midurethral sling procedures. 
With regard to complications, most of the complications reported were intraoperative minor 
ones, with little or no disabling effects provided they are recognized and treated 
intraoperatively. A very limited number of major complications (e.g. bowel, vascular, and 
nerve injuries, necrotizing fasciitis, ischiorectal abscess, urethrovaginal fistulas, sepsis, and 
patient deaths) have been reported after placement of midurethral slings. Deng et al reported 
on the prevalence of major complications in the US Food and Drug Administration’s 
Manufacturer and User Facility Device Experience database, identifying 32 cases of vascular 
injuries, 33 bowel injuries, and 8 patient deaths after TVT placement (Deng et al, 2007). 
A new terminology and classification system has been developed by the International 
Urogynecological Association (IUGA) and the International Continence Society (ICS) for full 
description of all possible physical complications related directly to the insertion of 
prostheses (meshes, implants, tapes) & grafts in female pelvic floor surgery (figure 4). A key 
advantage of a standardized classification is that all parties involved in female pelvic floor 
surgery including surgeons, physicians, nurses, allied health professionals and industry will 
be referring to the same clinical issue. It is anticipated that a category (C), time (T), and site 
(S) - (CTS) codified table of complications will be a necessary part of reports of surgical 
procedures relevant to this document. With a standardized classification in place, quicker 
assessment of adverse events will be achieved together with uniform reporting of 
prosthetic-related complications (Haylen et al, 2011). 
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Fig. 4. A classification by category (C), time (T), and site (S) of complications directly related 
to the insertion of prostheses (meshes, implants, tapes) or grafts in female pelvic floor 
surgery (Haylen et al, 2011). 
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2.4.1 Intraoperative and early postoperative complications 
Bladder perforation: occur during trocar passage in the retropubic space, it is a common 
intraoperative complication with reported rates of 0.7% to 24%. (Laurikainen et al, 2007; 
Andonian et al, 2005). Incidence of perforation increases with poor surgeon experience with 
the procedure or in recurrent cases. Bladder perforation is suspected intraoperatively by 
observation of hematuria after trocar passage and diagnosed by cystoscopy. Perforation is 
easily treated by correct reinsertion of the trocar and catheter drainage for 2–4 days. TOT 
avoids the needle passage in the retropubic space, and hence bladder perforation is much 
lower than that of TVT. 
Bleeding and retro-pubic hematoma: ranges from 0.7% to 8% (Laurikainen et al, 2007; 
Rezapour et al, 2001c) and in majority of cases minor bleeding occur during vaginal 
dissection and easily controlled. Sometimes excessive bleeding may lead to retropubic 
hematoma formation usually arises from pelvic floor veins, epigastric, external iliac or 
obturator vessels injury due to inadvertent trocar passage if laterally directed or externally 
rotated during the course of insertion. Hematomas size < 100 ml usually asymptomatic, 
between 100 - 200 ml cause moderate pain, while those >300 ml associated with severe pain 
and require surgical evacuation of Retzius space (Flock et al, 2004). As perforation, bleeding 
is not a common complication in TOT procedures, with reported rate 0% to 2% (Barber et al, 
2006; Costa et al, 2004). 
Bowel perforation: a very rare (< 0.007%) (Costantini et al, 2007) but serious complication 
and may be fatal.  A recent review revealed 7 deaths that occurred after TVT placement of 
which 6 were associated with bowel injury (Nygaard and Heit, 2004). Bowel perforation is 
not reported with TOT procedures. Risk factors for bowel injury include previous pelvic and 
abdominal surgery due to presence of adhesions in the retropubic space. 
2.4.2 Late postoperative complications 
De novo urgency: The rate of de novo urgency after midurethral slings placement as 
reported in literature ranges from 7.2% to 25% (Costantini et al, 2007). The mechanisms of 
de novo urgency after midurethral slings procedures are poorly understood. Combined 
outlet obstruction and urethral irritation by the sling has commonly been used as an 
explanation. TOT procedure is usually associated with a lower rate of de novo urgency than 
TVT (Juanos et al, 2011). Meanwhile, such complication usually does not improve by time. 
Holmgren et al reported 14.5% of de novo urgency after long term follow-up of 5.2 years 
after TVT (Holmgren et al, 2007). 
Groin and thigh pain: On the other hand, TOT procedure has a significant risk of post- 
operative groin and thigh pain. This pain was observed with range of 5% to 26%. 
(Meschia et al, 2007; Dobson et al, 2007). However, the pain is usually transient and 
resolves spontaneously within a few months in most of cases. The exact etiology of this 
pain remains unknown but it may be related to the tape’s presence in the adductor 
muscles or the foreign body reaction to the tape lying in proximity to peripheral obturator 
nerve branches or secondary to the trauma to the obturator membrane and muscles 
during the procedure. 
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Bladder Outlet Obstruction: Postoperative obstruction is another challenging complication 
after a mid urethral sling procedure which varies from urinary retention (temporary or 
permanent), difficulty emptying or a weak urinary stream. Obstruction usually arises from 
excessive tension placed over the midurethra by the tape. The reported rates of 
postoperative obstruction after TVT range from 1.9% to 19.7% (Abouassaly et al, 2004; 
Barber et al, 2006), and after TOT the rates actually vary from 0% to 15.6% (Fischer et al, 
2005; Delorme et al, 2004). Although urine retention and voiding dysfunction are thought to 
be less common after TOT approach, a recent multicenter randomized trial did not reveal 
significant differences in postoperative urinary retention between the TVT and TOT (6% and 
3%, respectively) (Barber et al, 2008). Early postoperative transient urinary retention could 
be treated with intermittent sterile self-catheterisation or indwelling catheter and usually 
resolve spontaneously within 12 wk with restoration of complete bladder emptying in the 
majority of cases. If no improvement occur, early simple sling lysis should be considered or 
suburethral tape transaction. 
Genitourinary erosion: it is the most frequent and distressing complication after synthetic 
midurethral sling operations. Costantini and colleagues reported erosion rates after 
midurethral sling operations based on ranges as reported in the literatures a range from 
0.7% - 33%, 2.7% - 33% and 0.5% - 0.6% for vaginal, urethra and urinary bladder erosion 
respectively (Costantini et al, 2007).  
The etiology of the erosion is multifactorial and includes inadequate closure of vaginal wall 
incision, extensive or incorrect plane of dissection, wound infection, mesh rejection, early 
sexual activity, tape rolling and abnormal vaginal epithelium i.e. atrophic, scarred or 
otherwise compromised vaginal mucosa as in post-menopausal women or after previous 
vaginal surgery and unrecognized vaginal laceration injury during trocar passage. The sling 
material also plays an important role in this complication.  
Patients with genitourinary erosion may be asymptomatic discovered on routine follow-up 
or presented with a group of symptoms which raise the suspicion of its diagnosis such as 
pain, dyspareunia, dysuria, discharge and/or bleeding from the urethra or vagina or tape 
palpable to the patient or partner. Hammad et al, reported that 35% of vaginal erosions were 
asymptomatic and erosion was discovered on routine follow-up (Hammad et al, 2005). 
Kobashi et al seemed to confirm these data. In > 90 women who received a polypropylene 
mesh for the treatment of SUI, 3 developed vaginal erosion, but only 1 had symptoms such 
as pain, discomfort during sexual activity, and vaginal discharge and erosion was 
discovered during a routine check-up (Kobashi et al, 2003). Most cases occur in the first few 
months after surgery but they can also happen much later.  
Mesh erosion may be treated with conservative measures or surgically treated depends on 
the erosion site and size, mesh material, and local tissue condition. Surgical approach ranges 
from partial simple excision of the exposed mesh to surgical exploration for total graft 
removal and tissue reconstruction with a Martius flap.  
Conservative management with observation might be a viable option if erosion is limited to 
the vagina and the sling were made of autologous, allograft and new, loosely woven 
polypropylene material because the latter provides large interstices, which favour tissue 
ingrowth and healing (Duckett and Constantine, 2000). While some authors stated that 
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polypropylene tape erosion should be treated with complete mesh removal, without regard 
to erosion site, size, or local tissue condition (Sweat et al, 2002). Vaginal erosion of synthetic 
materials, such as polyester and silicone slings, should also be treated with mesh removal 
because epithelialisation over these materials is unlikely (Duckett and Constantine, 2000; 
Stanton, Brindley and Holmes, 1985).  
If the vaginal erosion is small (1 cm) and local tissue does not appear infected, 
spontaneous healing by epithelialisation may occur in 6 to 12 weeks with pelvic rest alone 
(Kobashi and Govier, 2003). If conservative management is unsuccessful or the erosion is 
(1 cm), the exposed mesh may be excised with the patient under local anesthesia with 
vaginal closure after the edges have been freshened. Erosions with copious vaginal 
discharge or if local tissue appears to be infected may require more extensive resection of 
the mesh. Surgery is recommended when erosion involves the lower urinary tract 
(bladder or urethra), independently of sling materials (Clemens et al, 2000; Duckett and 
Constantine, 2000). A recent meta-analysis of polypropylene midurethral slings revealed 
a possible trend toward increased erosion rates after TOT approach (OR 1.5, 95% CI 0.51–
4.4) (Latthe et al, 2007). 
Although rare, erosion of mesh into the urethra can occur. A recent large retrospective series 
of TVT revealed urethral erosion in 0.3% of cases (Karram et al, 2003). 
With the new classification system of IUGA and ICS the description of the complications 
related to midurethral slings especially genitourinary erosion now become standardized 
and easy as shown in some the following reported cases of complication related to the use of 
midurethral tapes (figures 5, 6, 7) 
 
 
 
 
Fig. 5. 52 year old female underwent a transobturator tape. At 6 weeks, she was cured of her 
USI and reported no vaginal discharge. Vaginal examination revealed a smaller mesh 
exposure away from vaginal suture line. Classification: 2A T2 S2 (Haylen et al, 2011) 
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Fig. 6. A 47-year-old woman underwent a transoburator tape for USI. At 5 months follow-
up, she reported vaginal discharge. Clinically she was febrile at 38°C with a large sling 
extrusion as depicted. Classification: 3C T3 S1 (Haylen et al, 2011) 
 
Fig. 7. 65-year-old with urinary incontinence underwent a multifilament transobturator 
sling. At 14 months follow up, she experienced severe pelvic pain and vaginal discharge. 
Clinical examination revealed hyperthermia to 40°C, (i) sling exposure at right vaginal 
sulcus and (ii) severe cellulitis in the genito-crural fold. Classification: 3C T4 S2; (ii) 6C T4 S3 
(Haylen et al, 2011) 
3. Use of biodegradable materials 
3.1 Introduction  
The perfect implant material currently is not available yet, but in general surgery there is 
now a consensus, that low weight, large pore (macroporus), monofilament synthetic 
materials are preferable. However, still serious local complications (e.g. erosion and 
infection) may occur and related to an increased foreign body reaction. Subsequently, 
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biologic implants were introduced in an effort to reduce the local complications associated 
with synthetic materials without compromising the surgical results.  
Biological xenograft is a mammalian extracellular matrix (ECM) composed of laminin, 
fibrinectin, elastin, and collagen. Tissue sources from which xenografts are chosen include: 
porcine (small intestine, dermis), bovine (pericardium, fetal, dermis) and equine. Collagen 
based implants can either be cross-linked or not. Cross-linking protects the implant against 
degradation by collagenases, so that they remain intact very long, if not ever. At present, 
most xenogenic materials are from porcine source and it is the most commonly used, as 
bovine material became less acceptable. Production is strictly controlled by Food and Drug 
Administration (FDA) guidelines, which include knowledge of the animal herd, vaccination 
status, feed source, abattoir approval and bovine spongiform encephalopathy clearance 
(Deprest et al, 2006).  
We will discuss below the role of Small intestinal submucosal (SIS) graft as a futuristic 
biodegradable implant to substitute synthetic slings in the treatment of female SUI. 
3.2 Small intestinal submucosal (SIS) graft  
SIS xenograft is an acellular, nonimmunogenic, biodegradable, biocompatible, collagen 
matrix manufactured from porcine small intestinal submucosa, which could induce native 
tissue regeneration in various organs.  
3.2.1 Clinical applications of SIS 
SIS graft has gained popularity in the field of urogynecology and reconstructive surgery. 
Promising results have been reported with the use of SIS as a bladder and urethral 
substitute material in animals (Kropp, 1998a; Kropp et al, 1998b; Chen, Yoo and Atala, 
1999). Also, SIS has been used in humans undergoing urogenital procedures such as 
cystoplasties, ureteral reconstructions, penile chordee, and even urethral reconstruction for 
hypospadias and strictures (Dedecker et al, 2005; Atala et al, 1999; Le Roux, 2005; Kassaby 
et al, 2003; Sharma and Secrest, 2003; Liatsikos et al, 2001). In the field of urinary 
incontinence, SIS has been used with encouraging results in treatment of postprostatectomy 
incontinence (Jones et al, 2005a), neuropathic incontinence (Misseri et al, 2005), and SUI 
(Wiedemann and Otto, 2004; Rutner et al, 2003; Jones et al, 2005b; Farahat et al, 2009). 
Practical concerns regarding the use of the SIS implant in clinical practice: The first practical 
concern is related to the graft biocompatibility and how the tissue would react to the 
implant. The second practical concern is related to the biomechanical properties of the SIS 
sling and its suitability for curing SUI (Farahat et al, 2009). 
3.2.2 Graft biocompatibility  
SIS is made by a way that all cells responsible for an eventual immune response are 
removed, but the ECM and natural growth factors are left intact. It contains collagen, 
growth factors TGF-beta and FGF-2 (Wiedemann and Otto, 2004). Many clinical trials and 
histopathological studies support the fact that the SIS graft has excellent biocompatibility as 
evidenced by lack of significant immunological reaction, foreign body reaction, and chronic 
inflammatory reaction (figure 8). In addition, the SIS sling is well known for its strength, 
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durability, and resistance to infection (Badylak, 2004; Jankowski, et al, 2004; Wiedemann 
and Otto, 2004; Rutner et al, 2003). 
      
Fig. 8. First histopathological results for SIS pubovaginal slings show: submucosal biopsy 
with A) minimal SIS residues (red arrows) - B) minimal chronic inflammatory infiltration 
(Wiedemann and Otto, 2004). 
3.2.3 Biomechanical properties 
SIS is degraded in 4 to 12 weeks by a “constructive” remodeling process that replaces the 
graft gradually by host connective tissue (Clarke et al, 1996; Prevel et al, 1995). Tensiometric 
strength initially decreases down to 45% 10 days after implantation, but by 1 month it is 
identical to that of the native tissue (Badylak et al, 2001). The task of the SIS sling is mainly 
to act as a scaffold that allows in-growth and structural organization of the native host 
tissue. The implant actively supports connective and epithelial tissue ingrowth and 
differentiation, as well as deposition, organization, and maturation of ECM components that 
characterize site-specific tissue remodeling. This phenomenon has been called smart tissue 
remodeling (Badylak, 1993) and it is important to note that the balance between implant 
degradation and host incorporation results in a dynamic implant strength response. The 
strength of the SIS sling is expected to be the net result between SIS degradation and tissue 
regeneration. Degradation rates that are too rapid or reconstruction rates that are too slow 
can result in transient minimum strengths that are below the critical threshold. Supposedly, 
this carries increased risk of recurrence of incontinence symptoms after an initial successful 
anti-incontinence surgery (Jankowski et al, 2004). 
3.2.4 Outcome of the SIS Sling  
The suitability of the SIS sling is better reflected by the clinical outcome. In terms of clinical 
efficacy in correction of SUI, the results of different studies showed that SIS was able to 
provide a strong suburethral support and durable clinical results (table 7). 
Rutner et al, reported in their work utilizing SIS as a pubovaginal slings in the treatment of 
female SUI that all patients had minimal local reactions and pelvic pain; no cases of erosion 
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or extrusion were noted. The authors also performed a biopsy for cases which required 
reoperation for correction of incontinence. They observed absence of the implanted graft on 
gross examination. Microscopically, only a few remnants of the SIS (< 0.4 mm) could be 
found (Rutner et al, 2003). Farahat et al, reported also using SIS as TVT (figure 9) in the 
treatment of female SUI that the SIS sling was accepted nicely by the tissue after 12 months. 
No erosion, extrusion, or severe inflammatory reactions were noted. Most reactions were 
mild and usually observed as early as 10 days or as late as 45 days after the procedure. Most 
reactions were well tolerated and resolved spontaneously (Farahat et al, 2009). 
 
Author Number of 
patients 
Patient 
group 
Technique of SIS graft 
placement 
Treatment 
outcomes 
(% cured) 
Rutner et al, 2003 152 SUI Pubovaginal slings + 
bone anchoring 
93.4% 
Jones et al, 2005b 34 SUI TVT 80% 
Farahat et al, 2009 17 SUI TVT 82.3 % 
Table 7. Treatment outcome of SIS graft. 
 
Fig. 9. SIS as TVT sling (Farahat et al, 2009).  
3.2.5 SIS graft complications  
However, unlike most reports confirming the safe use of the SIS graft in the treatment of 
SUI, Ho et al (Ho et al, 2004) reported inflammatory reactions (figure 10) at the abdominal 
incision (but none at the vaginal incision) in 6 out of 10 patients treated with the 8-ply SIS 
sling. Most cases resolved with minimal or no intervention. Abscess formation was observed 
in 2 patients.  
John et al (John et al, 2008) used both the Cook 4-ply and the 8-ply Stratasis- TF in 16 
women with SUI. They reported intense inflammatory complications in 5 patients (nearly 
one third). Most of the inflammatory reactions were related to the suprapubic region rather 
than near the vagina or urethra. Four of the 5 patients with complications had the new 8-ply 
Stratasis-TF. The remaining patient had the 4-ply SIS; however, this patient had a 
concomitant extensive pelvic floor reconstruction by a gynecologist prior to placement of the 
SIS sling. Apparently adding more layers to the SIS graft material may have a contributing 
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role in inflammatory reactions, because these high complication rates were not observed 
with the older 1-ply and 4-ply formulations (John et al, 2008; Santucci and Barber, 2005). 
No study till now compared the 1-ply, 4-ply, and 8-ply SIS grafts in humans. 
 
Fig. 10. CT shows inflammation of subcutaneous tissue (A) and along arms of the SIS sling 
(Ho et al, 2004). 
The SIS graft material is well accepted by the host tissue, and considered safe and effective 
with lower incidence of erosion and infection than the synthetic midurethral slings. 
However, Long period of follow up are still required to support the durability of these 
preliminary results. 
4. Stem cell therapy 
4.1 Introduction 
Stem cells therapy for the regenerative repair of the deficient rhabdosphincter has been the 
most recent advance in incontinence research. The ultimate goal has been to achieve a 
permanent cure for SUI by restoration of the intrinsic and extrinsic urethral sphincter and 
the surrounding connective tissue, including peripheral nerves and blood vessels. Overall, 
the aim of stem cell therapy is to replace, repair, or enhance the biological function of 
damaged tissue or organs.  
4.2 Cell source  
There are two general types of stem cells potentially useful for therapeutic treatment, 
embryonic stem cells (ESCs) and adult stem cells (Novara and Artibani, 2007). The practical 
use of ESCs has ethical limitations inherent to cell harvesting from fetal tissue and 
histocompatibility problems. (Edwards, 2007). In contrast, adult stem cells have no 
significant ethical issues related to their use and have more limited differentiation potential 
which makes them safer. Tissues engineering therapies are based on autologous multipotent 
stem cells, of which bone marrow stromal cells are most often used. The bone marrow 
stromal cells contain mesenchymal stem cells (MSCs) that are capable of differentiating into 
into adipogenic, osteogenic, chondrogenic and myogenic cells (Pittenger et al, 1999; Ferrari 
et al, 1998; Prockop, 1997; Dezawa et al, 2005), However, bone marrow compartment usage 
has significant limitations due to its painful nature which usually require general or spinal 
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anesthesia, and low number of (MSCs) are obtained (Pittenger et al. 1999). Muscle derived 
stem cells (MDCs) and adipose derived stem cells (ADSCs) are advantageous because they 
can be easily obtained in large quantities under local anesthesia (Rodríguez et al,. 2006; 
Strem et al, 2005).  
4.2.1 Bone marrow-derived stem cells (BMSCs)  
Bone marrow-derived stem cells (BMSCs) have been most widely studied of all 
mesenchymal stem cells. BMSCs have been used for the regeneration of cardiac muscle 
(Sadek et al, 2009), bladder detrusor muscle (Kanematsu et al, 2005), anal sphincter muscle 
(Lorenzi et al, 2008), and many other structures (El Backly and Cancedda, 2010). Drost et al. 
in a pilot study transplanted autologous BMSCs into injured rat urethral sphincter. The 
cultured BMSCs were injected periurethrally 1 week after the urethral injury. Both 
histological and immunohistochemistry evaluation showed that transplanted BMSCs 
survived and differentiated into peripheral nerve cells and striated muscle cells compared to 
the cell-free group (Drost et al, 2009). 
4.2.2 Adipose-derived stem cells 
Adipose derived stem cells (ADSCs), is a pluripotent cells which have the ability to 
differentiate into cells of the same and of another germ layer, such as adipogenic, 
chondrogenic, neurogenic, myogenic and osteogenic cells (Roche et al, 2010). In the field of 
urinary incontinence ADSCs are of special interest for mesodermal and neuronal 
regeneration and to promote revascularization. Bacou et al, reported that transplantation of 
ADSCs increases mass and functional capacity of damaged skeletal muscle. They can 
express specific striated muscle markers (eg, desmin, myod1, myogenin, myosin heavy 
chain), form multinucleated cells characteristic of myotubules (Bacou et al, 2004). Also, 
ADSCs can express nerve growth factor at the time of neural differentiation. Zhang et al, 
reported that neural-differentiated ADSCs present glial characteristics and promote nerve 
regeneration, after 7 days of transplantation in a rat model in vivo (Zhang et al, 2010). 
Periurethral injection of ADSCs in an immune-competent, incontinent rat model with SUI, 
exhibited in vivo differentiation into smooth muscle cells and improved urethral resistance 
(Lin et al, 2010). Fu et al. injected predifferentiated ADSCs with 5-azacitidine periurethrally 
into incontinent rats. A significant difference in bladder capacity and leak point pressure 
was observed after 3 months of follow-up between the control group and the pretreated 
group. Also increased number of myoblasts under the mucosa and expression of α-smooth 
muscle actin was observed 3 months after implantation (Fu et al, 2010).  
4.2.3 Muscle derived stem cells (MDCs)  
Muscle-derived stem cells (MDSCs) can naturally differentiate to multinucleated muscle 
fibers and display stem cell characteristics (Seale and Rudnicki, 2000). MDSCs have also the 
ability to undergo long-term proliferation, self-renewal, and multipotent differentiation, 
including differentiation toward endothelial and neuronal lineages (Lee et al, 2000; Qu-
Petersen et al, 2002). Cannon et al, reported that MDSCs are capable of restoring muscular 
contraction of the urethral sphincter 2 weeks after injection (Cannon et al, 2003). MDSCs 
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also may improve neurogenic bladder dysfunction in animal models by reconstitution of 
damaged peripheral nerve cells (eg, Schwann cells, perineum) and vascular cells (eg, 
vascular smooth muscle cells, pericytes, endothelial cells) (Nitta et al, 2010). For the 
treatment of SUI myoblasts have been injected to the striated urinary sphincter of a pig 
model. The animals have shown an increase in urethral pressure profile and muscular 
myofibrils (Mitterberger et al, 2008).  
Advantages of MDSCs injection therapy over conventional treatments for SUI: 
1. MDSCs that are derived from the incontinent patient (autologous cell transplantation) will 
not cause an immunogenic or allergic reaction (Yokoyama et al, 2001a; Lee et al, 2004). 
2. MDSCs are uniquely different from fibroblasts and smooth muscle cells since MDSCs 
will fuse to form post-mitotic multinucleated myotubes. This limits persistent 
expansion and risk of obstruction that may occur with other cell sources such as 
fibroblasts (Kwon et al, 2006). 
3. MDSCs form contractile myotubes and myofibers that become innervated into the host 
muscle by activating the intrinsic nerve regeneration and formation of neuromuscular 
junctions. Therefore, they can not only serve as a bulking agent, but they are also 
physiologically capable of improving urethral sphincter function (Chancellor et al, 
2000; Yokoyama et al, 2001b; Huard et al, 2002; Hoshi et al, 2008). 
4.3 Isolation of muscle-derived stem cells in humans  
Mitterberger M et al. and Strasser H et al. reported biopsy in the right or left upper limb 
(biceps muscle) to obtain 0.32 to 2 cm3 of muscle tissue (figure 11). At the same time, 250 mL 
of blood were drawn for autologous serum (Mitterberger et al, 2008; Strasser et al, 2007b).  
 
Fig. 11. Diagram showing autologous stem cell injection therapy for SUI. Autologous stem 
cells are obtained with a biopsy of tissue, the cells are dissociated and expanded in culture, 
and the expanded cells are implanted into the same host. MDSCs = muscle derived stem 
cells (Jankowski et al, 2008) 
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Myoblasts and fibroblasts are separated from connective tissue by centrifugation and 
enzymatic digestion with type I collagenase. Myoblasts are cultured in Ham’s F10 medium 
supplemented with 20% autologous serum, and fibroblasts in DMEM (Dulbecco’s modified 
Eagle medium) and Ham’s F12 medium with 10% autologous serum. Cells are accepted 
when they reach 80% confluence. After 6-8 weeks in culture, fibroblasts and myoblasts are 
harvested separately by tripsinization and washing with centrifugation. Cell quality is 
assessed by immunohistochemistry, immunofluorescence, and fluorescence-activated cell 
sorting. Anti-desmin, vimentin, CD56, CD34 and ASO2 antibodies are used to differentiate 
myoblasts from fibroblasts. Fusion capacity of myoblasts is measured in differentiation 
medium without autologous serum to assess their viability, and cells are counted in each 
culture using the Neubauer chamber (figure 12). Once the cells are “harvested”, they are 
transferred in adequate numbers to sterile syringes, separating myoblasts from fibroblasts. 
Myoblasts are suspended in 1.4 mL of DMEM/F12 with 20% autologous serum, and 
fibroblasts in 1 mL of DMEM/F12 with 20% autologous serum mixed with collagen as 
transport material to prevent cell migration from the injection site, because fibroblasts are 
mobile following application. Collagen has been shown to stabilize cells so that they remain 
in place and produce their own extracellular matrix (Strasser et al, 2007b). 
 
Fig. 12. Characterisation of cells: (A) Immunohistochemical image of human myoblasts 
stained with antidesmin antibodies. (B) Immunofl uorescence image of human fibroblasts 
stained with antivimetin antibodies. (C) Fluorescent antibody cell sorter (FACS) analysis of 
myoblast cell culture showing that 97% of the myoblasts are positive for CD56 antibodies. 
(D) Phase-contrast microscope image of multinucleated myotubes (marked with arrows) 
that have formed after fusion of mononucleated myoblasts in diff erentiation medium 
(Strasser et al, 2007b). 
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4.4 Transurethral ultrasound (TUUS) guided injection of stem cell  
At the beginning of the cell injection, the TUUS probe (8 Ch, 15– 20 MHz) was carefully 
inserted into the urethra. The urethral wall and the rhabdosphincter were visualized. A 
specially designed patent-pending injection device was used for precisely adjusted injection 
of several small portions. First, 15–18 portions of the myoblast suspension were injected 
directly into the omega-shaped rhabdosphincter at two different levels. Then, 25–30 depots 
of the fibroblast/collagen suspension were injected into the submucosa circumferentially at 
three levels (Figure 13). After implantation of the cells the patients were instructed to 
perform PFT and FES for 4 wk postoperatively to support integration of the cells and to 
improve formation of new muscle tissue (Strasser et al, 2007). 
 
Fig. 13. Cross-sectional ultrasonography images of the urethra and the rhabdosphincter (A) 
The tip of the needle (marked with an arrow) is positioned at the inner aspect of the 
rhabdosphincter (RS) for injection of myoblasts. (B) The tip of the needle is placed at the 
outer aspect of the submucosa (SM) for injection of fibroblasts (Strasser et al, 2007b). 
4.5 Clinical results of stem cell therapy 
Few human trials have been conducted using autologous derived stem cells in the treatment 
of female SUI, which mainly involved the use of MDSCs. Stem cell therapy, shows an early 
encouraging results and these results suggest the ability of pure cellular therapy to treat 
female SUI (Table 8). 
Strasser et al. conducted the first clinical experiments in women with SUI. 42 women 
suffering from SUI were recruited and subsequently treated with transurethral 
ultrasonography- guided injections of autologous myoblasts and fibroblasts obtained from 
skeletal muscle biopsies. After a follow-up of 12 months incontinence was cured in 39 
women (Strasser et al, 2007a). In another trial 42 women were randomly assigned to receive 
transurethral ultrasonography guided injections of autologous myoblasts and fibroblasts, at 
12-months’ follow-up, 38 of the 42 women injected with autologous cells were completely 
continent (Strasser et al, 2007b). Mitterbarger et al. studied 20 female patients suffering from 
SUI after TUUS guidance injection of autologous myoblasts and fibroblasts. At 1 year 
follow-up 18 patients were cured and 2 patients improved. At 2 years after therapy 16 of the 
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18 patients presented as cured, 2 others were improved, and 2 were lost to follow-up 
(Mitterbarger et al, 2008a). Other studies have been reported early good results for stem cell 
injection in female with SUI (Carr et al, 2008; Herschorn et al, 2010).  
Not only stem cell injection therapy is limited to the field of female SUI, however its usage 
has been extended to treat males with post-prostatectomy incontinence (Mitterbarger et al, 
2008b; Yamamoto et al, 2010).  
 
Clinical study Patients (n) Patient 
group 
Stem cell 
source 
Symptomatic 
improvement 
Strasser et al, 2007a 63 
(42) women 
(21) men 
SUI MDSC, 
fibroblasts 
85% 
Strasser et al, 2007b 42 women SUI MDSC, 
fibroblasts 
91% 
Mitterbarger et al, 
2008a 
20 women SUI MDSC, 
fibroblasts 
90% at 1 yr 
89% at 2 yr 
Carr et al, 2008 8 women SUI MDSCs 63% 
Herschorn et al, 2010 29 women SUI MDSC 
 
50% cured 
Table 8. Results of the first clinical studies have recently become available. 
In general, stem cell injection therapy into the middle urethra may restore the contractile 
response of the striated muscle and rhabdosphincter. Early results were encouraging with 
no reported serious side effects. Autologous MDSCs and ADSC pure injection therapy may 
be a promising treatment to restore urethral sphincter function. These promising early 
clinical results warrant further evaluation to validate results, determine durability and focus 
on safety and possible adverse reactions. 
5. References 
Abrams P, Cardozo L, Magnus F, et al. (2002). The standardization of terminology of lower 
urinary tract function: report from the standardization sub-committee of the 
International Continence Society. Neurourol Urodynam, Vol. 21, pp. 167–178 
Abouassaly R, Steinberg JR, Lemieux M, et al. (2004). Complications of tension-free vaginal 
tape surgery: a multi-institutional review. BJU Int, Vol. 94, pp. 110  
Aigmueller T, Trutnovsky G, Tamussino K, et al. (2011). Ten-year follow-up after the 
tension-free vaginal tape procedure. American Journal of Obstetrics and Gynecology. 
Article in Press. doi:10.1016/j.ajog.2011.07.010 
Amid P. (1997). Classification of biomaterials and their relative complications in an 
abdominal wall hernia surgery. Hernia, Vol. 1, pp. 15–21 
www.intechopen.com
Futuristic Concept in Management  
of Female SUI: Permanent Repair Without Permanent Material 
 
313 
Andonian S, Chen T, St-Denis B, et al. (2005). Randomized clinical trial comparing 
suprapubic arch sling (SPARC) and tension-free vaginal tape (TVT): one-year 
results. Eur Urol, Vol. 47, pp. 537 
Angioli R, Plotti F, Muzii L, et al. (2010). Tension-Free Vaginal Tape Versus Transobturator 
Suburethral Tape: Five-Year Follow-up Results of a Prospective Randomised Trial. 
European Urology, Vol. 58, pp. 671–677 
Atala A, Guzman L, Retik AB. (1999). A novel inert collagen matrix for hypospadias repair. J 
Urol, Vol. 162, pp. 1148–51 
Bacou F, el Andalousi RB, Daussin PA, et al. (2004). Transplantation of adipose tissue-
derived stromal cells increases mass and functional capacity of damaged skeletal 
muscle. Cell Transplant, Vol. 13, pp. 103–111 
Badylak SF. (1993). Small intestinal submucosa (SIS): a biomaterial conducive to smart tissue 
remodeling. In: Bell E, ed. Tissue Engineering: Current Perspectives, 179-189, 
Cambridge, MA: Burkhauser Pub 
Badylak SF, Kokini K, Tullius B, et al. (2001). Strength over time of a resorbable bioscaffold 
for body wall repair in a dog model. J Surg Res, Vol. 99, pp. 282–287  
Badylak SF. (2004). Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. 
Transplant Immunology, Vol. 12, pp. 367-377 
Barber MD, Gustilo-Ashby AM, Chen CC, et al. (2006). Perioperative complications and 
adverse events of the MONARC transobturator tape, compared with the tension-
free vaginal tape. Am J Obstet Gynecol, Vol. 195, pp. 1820 
Barber MD, Kleeman S, Karram MM, et al. (2008). Transobturator tape compared with 
tension-free vaginal tape for the treatment of stress urinary incontinence: a 
randomized controlled trial. Obstet Gynecol, Vol. 111, pp. 611 
Botlero R, Urquhart DM, Davis SR, et al. (2008). Prevalence and incidence of urinary 
incontinence in women: review of the literature and investigation of 
methodological issues. Int J Urol, Vol. 15, pp. 230–4 
Cannon TW, Lee JY, Somogyi G, et al. (2003). Improved sphincter contractility after 
allogenic muscle-derived progenitor cell injection into the denervated rat urethra. 
Urology, Vol. 62, pp. 958–963 
Carr LK, Steele D, Steele S, et al. (2008). 1-year follow up of autologous muscle-derived stem 
cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic 
Floor Dysfunct, Vol. 19; pp. 881–883. 
Chen F, Yoo JJ, Atala A. (1999). Acellular collagen matrix as a possible ‘‘off the shelf’’ 
biomaterial for urethral repair. Urology, Vol. 54, pp. 407–9 
Cindolo L, Salzano L, Rota G, et al. (2004). Tension-free transobturator approach for female 
stress urinary incontinence. Minerva Urol Nefrol, Vol. 56, pp. 89–98 
Clarke KM, Lantz GC, Salisbury SK, et al. (1996). Intestine submucosa and polypropylene 
mesh for abdominal wall repair in dogs. J Surg Res, Vol. 60, pp. 107–114 
Clemens JQ, DeLancey JO, Faerber GJ, et al. (2000). Urinary tract erosions after synthetic 
pubovaginal slings: diagnosis and management strategy. Urology, Vol. 56, pp. 589–
94 
Chancellor MB, Yokoyama T, Tirney S, et al. (2000). Preliminary results of myoblast injection 
into the urethra and bladder wall: a possible method for the treatment of stress 
www.intechopen.com
 
Urinary Incontinence 
 
314 
urinary incontinence and impaired detrusor contractility. Neurourol Urodyn, Vol. 19, 
pp. 279–87 
Costa P, Grise P, Droupy S, et al. (2004). Surgical treatment of female stress urinary 
incontinence with a trans-obturator-tape (T.O.T.) Uratape: short term results of a 
prospective multicentric study. Eur Urol, Vol. 46, pp. 102 
Costantini E, Lazzeri M & Porena M. (2007). Managing Complications after Midurethral 
Sling for Stress Urinary Incontinence. EAU - EBU update series, Vol. 5, pp. 232-40 
Daneshgari F, Kong W and Swartz M. (2008). Complications of Mid Urethral Slings: 
Important Outcomes for Future Clinical Trials. The Journal of Urology, Vol. 180, pp. 
1890-1897 
Dedecker F, Grynberg M, Staerman F. (2005). Small intestinal submucosa (SIS): prospects in 
urogenital surgery. Prog Urol, Vol. 15, pp. 405–7  
Deffieux X, Donnadieu AC, Porcher R, et al. (2007). Long-term results of tension-free vaginal 
tape for female urinary incontinence: follow-up over 6 years. Int J Urol, Vol. 14, pp. 
521–526 
DeLancey JO. (1994). Structural support of the urethra as it relates urinary incontinence: the 
hammock hypothesis. Am J Obstet Gynaecol, Vol. 170, No. 20, pp. 1713 
De Leval J. (2003). Novel Surgical Technique for the Treatment of Female Stress Urinary 
Incontinence: Transobturator Vaginal Tape Inside-Out. European Urology, Vol. 44, 
pp. 724–730 
DeLorme E. (2001). Transobturator tape urethral suspension: mini-invasive procedure in the 
treatment of stress urinary incontinence in women. Prog Urol, Vol. 11, pp. 1306–
1313 
Delorme E, Droupy S, de Tayrac R, et al. (2004). Transobturator tape (Uratape): a new 
minimally-invasive procedure to treat female urinary incontinence. Eur Urol, Vol. 
45, pp. 203  
Deng DY, Rutman M, Raz S, Rodriguez LV. (2007). Presentation and management of major 
complications of midurethral slings: are complications under-reported? Neurourol 
Urodyn, Vol. 26, pp. 46–52  
Deprest J., Zheng F. and Konstantinovic M, et al. (2006). The biology behind fascial defects 
and the use of implants in pelvic organ prolapse repair. Int Urogynecol J, Vol. 17, 
pp. S16–S25 
Dobson A, Robert M, Swaby C, et al. (2007). Trans-obturator surgery for stress urinary 
incontinence: 1 year follow-up of a cohort of 52 women. Int Urogynecol J Pelvic Floor 
Dysfunct, Vol. 18, pp. 27–32 
Drost AC, Weng S, Feil G, et al. (2009). In vitro myogenic differentiation of human bone 
marrow-derived mesenchymal stem cells as a potential treatment for urethral 
sphincter muscle repair. Ann N Y Acad Sci, Vol. 1176, pp. 135–143. 
Duckett JRA, Constantine G. (2000). Complications of silicone sling insertion for stress 
urinary incontinence. J Urol, Vol. 163, pp. 1835–7 
Dwyer PL. (2006). Evolution of biological and synthetic grafts in reconstructive pelvic 
surgery. Int Urogynecol J, Vol. 17, pp. S10–S15 
Dezawa M, Ishikawa H, Itokazu Y, et al. (2005). Bone marrow stromal cells generate muscle 
cells and repair muscle degeneration. Science, Vol. 309, pp. 314–7  
www.intechopen.com
Futuristic Concept in Management  
of Female SUI: Permanent Repair Without Permanent Material 
 
315 
Edwards RG. (2007). A burgeoning science of embryological genetics demands a modern 
ethics. Reprod Biomed Online, Vol. 15, pp. 34–40  
El Backly RM, Cancedda R: (2010). Bone marrow stem cells in clinical application: 
harnessing paracrine roles and niche mechanisms. Adv Biochem Eng Biotechnol, Aug 
27 (Epub ahead of print). 
Farahat Y, Eltatawy H, Haroun H et al: (2009). The Small Intestinal Submucosa (SIS) as a 
Suburethral Sling for Correction of Stress Urinary Incontinence: UroToday 
International Journal, Vol. 2/Iss 3/June doi:10.3834/uij.1944-5784.2009.06.02 
Fischer A, Fink T, Zachmann S, et al. (2005). Comparison of retropubic and outside-in 
transoburator sling systems for the cure of female genuine stress urinary 
incontinence. Eur Urol, Vol. 48, pp. 799  
Ferrari G, Cusella-De Angelis G, Coletta M, et al. (1998). Muscle regeneration by bone 
marrow-derived myogenic progenitors. Science, 279, pp. 1528–30  
Flock F, Reich A, Muche R, et al. (2004). Hemorrhagic complications associated with tension-
free vaginal tape procedure. Obstet Gynecol, Vol. 104, pp. 989 
Fu Q, Song XF, Liao GL, et al. (2010). Myoblasts differentiated from adipose-derived stem 
cells to treat stress urinary incontinence. Urology, Vol. 75, pp. 718–723 
Giberti C, Gallo F, Cortese P, et al. (2007). Transobturator tape for treatment of female stress 
urinary incontinence: objective and subjective results after a mean follow-up of two 
years. Urology, Vol. 69, pp. 703–707 
Grise P, Droupy S, Saussine C, et al. (2006). Transobturator tape for stress urinary 
incontinence with polypropylene tape and outside-in procedure: Prospective study 
with 1 year of minimal follow-up and review of transobturator tape sling. Urology, 
Vol. 68, 759–763 
Hammad FT, Kennedy-Smith A, Robinson RG. (2005). Erosions and urinary retention 
following polypropylene synthetic sling: Australasian survey. Eur Urol, vol. 47, pp. 
641–7 
Hannestad YS, Rortveit G, Sandvik H, et al. (2000). A community based survey of female 
urinary incontinnce: the Norwegian EPINCONT study. J Clin Epidemiol, Vol. 53, pp. 
1150–7 
Huard J, Yokoyama T, Pruchnic R, et al. (2002). Muscle-derived cell-mediated ex vivo gene 
therapy for urological dysfunction. Gene Ther, Vol. 9, pp. 1617–26 
Haylen BT,  Freeman RM,  Swift SE, et al. (2011). An International Urogynecological 
Association (IUGA) / International Continence Society (ICS) joint terminology and 
classification of the complications related directly to the insertion of prostheses 
(meshes, implants, tapes) & grafts in female pelvic floor surgery. Int Urogynecol J, 
Vol. 22, pp. 3–15 
Herschorn S, Carr L, Birch C, et al. (2010). Autologous muscle-derived cells as therapy for 
stress urinary incontinence: A randomized blinded trial. Neurourol Urodyn, Vol. 29, 
pp. 243–326 [abstract] 
Ho KL, Witte MN, Bird ET. (2004). 8-ply small intestinal submucosa tension-free sling: 
spectrum of postoperative inflammation. J Urol, Vol. 171, pp. 268-271 
Holmgren C, Nilsson S, Lanner L, et al. (2007). Frequency of de novo urgency in 463 women 
who had undergone the tension-free vaginal tape (TVT) procedure for genuine 
www.intechopen.com
 
Urinary Incontinence 
 
316 
stress urinary incontinence – a long-term follow-up. Eur J Obstet Gynecol, Vol. 132, 
pp. 5–121 
Hoshi A, Tamaki T, Tono K, et al. (2004). Reconstruction of radical prostatectomy-induced 
urethral damage using skeletal musclederived multipotent stem cells. 
Transplantation, Vol. 85, pp. 1617–1624 
Jankowski R, Pruchnic R, Hiles M, et al. (2004). Advances toward tissue engineering for the 
treatment of stress urinary incontinence. Rev Urol, Vol. 6, pp. 51-57 
Jankowski R, Pruchnic R, Wagner D et al. (2008). Regenerative Therapy for Stress Urinary 
Incontinence. Tzu Chi Med J, Vol. 20, pp. 169-176 
John TT, Aggarwal N, Single AK, et al. (2008). Intense inflammatory reaction with porcine 
small intestine submucosa pubovaginal sling or tape for stress urinary 
incontinence. Urology, Vol. 72, pp. 1036-1039 
Jones JS, Vasavada SP, Abdelmalak JB, et al. (2005a). Sling may hasten return of continence 
after radical prostatectomy. Urology, Vol. 65, pp. 1163-1167 
Jones JS, Rackley RR, Berglund R, et al. (2005b). Porcine small intestinal submucosa as a 
percutaneous mid-urethral sling: 2-year results. BJU Int, 96, pp. 103-106 
Juanos JL, Sanchez EB, Soler JP, et al. (2011). De novo urgency after tension-free vaginal tape 
versus transobturator tape procedure for stress urinary incontinence. European 
Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 155, pp. 229-32 
Kanematsu A, Yamamoto S, Iwai-Kanai E, et al. (2005). Induction of smooth muscle cell-like 
phenotype in marrow-derived cells among regenerating urinary bladder smooth 
muscle cells. Am J Pathol, Vol. 166, pp. 565–573. 
Karram MM, Segal JL, Vassallo BJ, et al. (2003). Complications and untoward effects of the 
tension-free vaginal tape procedure. Obstet Gynecol, Vol. 101, pp. 929 
Kassaby EA, Retik AB, Yoo JJ, et al. (2003). Urethral stricture repair with an off-the-shelf 
collagen matrix. J Urol, Vol. 169, pp. 170–3 Kobashi KC, Govier FE. (2003). 
Management of vaginal erosion of polypropylene mesh slings. J Urol, Vol. 169, 
pp.2242–3 
Kropp BP. (1998a). Small-intestinal submucosa for bladder augmentation: a review of 
preclinical studies. World J Urol, Vol. 16, pp. 262–5  
Kropp BP, Ludlow JK, Spicer D, et al. (1998b). Rabbit urethral regeneration using small 
intestinal submucosa onlay graft. Urology, Vol. 52, pp. 138–42 
Kwon D, Kim Y, Pruchnic R, et al: (2006). Periurethral cellular injection: comparison of 
muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue 
contractility in an animal model of stress urinary incontinence. Urology, Vol. 68, pp. 
449–454 
Latthe P, Foon R and Toozs-Hobson P. (2007). Transobturator and retropubic tape 
procedures in stress urinary incontinence: a systematic review and meta-analysis of 
effectiveness and complications. BJOG, Vol. 114, pp. 522 
Laurikainen E, Valpas A, Kivela A, et al. (2007). Retropubic compared with transobturator 
tape placement in treatment of urinary incontinence: a randomized controlled trial. 
Obstet Gynecol, Vol. 109, pp. 4 
Le Roux PJ. (2005). Endoscopic urethroplasty with unseeded small intestinal submucosa 
collagen matrix grafts: a pilot study. J Urol, Vol. 173, pp. 140–3 
www.intechopen.com
Futuristic Concept in Management  
of Female SUI: Permanent Repair Without Permanent Material 
 
317 
Liapis A, Bakas P and Creatsas G. (2010). Efficacy of inside-out transobturator vaginal tape 
(TVTO) at 4 years follow up. European Journal of Obstetrics & Gynecology and 
Reproductive Biology, Vol. 148, pp. 199–201 
Liatsikos EN, Dinlec CZ, Kapoor R, et al. (2001). Ureteral reconstruction: small intestine 
submucosa for the management of strictures and defects of the upper third of the 
ureter. J Urol, Vol. 165, pp. 1719–23 
Lin G, Wang G, Banie L, et al. (2010). Treatment of stress urinary incontinence with adipose 
tissue-derived stem cells. Cytotherapy, Vol. 12, pp. 88–95 
Lee JY, Qu-Petersen Z, Cao B, et al. (2000) Clonal isolation of muscle-derived cells capable of 
enhancing muscle regeneration and bone healing. J Cell Biol, Vol. 150, pp. 1085–100 
Lee JY, Paik SY, Yuk SH, et al. (2004) Long term effects of muscle-derived stem cells on leak 
point pressure and closing pressure in rats with transected pudendal nerves. Mol 
Cells, Vol. 18, pp. 309–313 
Lorenzi B, Pessina F, Lorenzoni P, et al. (2008). Treatment of experimental injury of anal 
sphincters with primary surgical repair and injection of bone marrow-derived 
mesenchymal stem cells. Dis Colon Rectum, Vol. 51, pp. 411–420. 
Mariappan P, Alhasso A, Ballantyne Z, et al.b(2007). Duloxetine, a Serotonin and 
Noradrenaline Reuptake Inhibitor (SNRI) for the Treatment of Stress Urinary 
Incontinence: A Systematic Review. European urology, Vol. 51, pp. 67–74 
Meschia M, Bertozzi R, Pifarotti P, et al. (2007). Peri-operative morbidity and early results of 
a randomised trial comparing TVT and TVT-O. Int Urogynecol J Pelvic Floor 
Dysfunct, Vol. 18, pp. 1257–1261 
Misseri R, Cain MP, Casale AJ, et al. (2005). Small intestinal submucosa bladder neck slings 
for incontinence associated with neuropathic bladder. J Urol, Vol. 174, pp. 1680-1682 
Mitterberger M, Pinggera GM, Marksteiner R, et al. (2007). Functional and histological 
changes after myoblast injections in the porcine rhabdosphincter. Eur Urol, Vol. 52, 
pp. 1736–1743. (Published erratum appears in Eur Urol 2008, 54:1208 
Mitterberger M, Pinggera GM, Marksteiner R, et al. (2008a). Adult Stem Cell Therapy of 
Female Stress Urinary Incontinence. European urology, Vol. 53, pp. 169-175 
Mitterberger M, Marksteiner R, Margreiter E, et al. (2008b). Myoblast and fibroblast therapy 
for post-prostatectomy urinary incontinence: 1-year follow-up of 63 patients. J Urol, 
Vol. 179, pp. 226–231. 
Morley R & Nethercliffe J. (2005). Minimally invasive surgical techniques for stress 
incontinence surgery. Best Practice & Research Clinical Obstetrics and Gynaecology, 
Vol. 19, pp. 925-940 
Neuman M & Shaare-Zedek MC. (2007). Training TVT SECUR: the first 150 teaching 
operations. Int Urogynecol J, Vol. 18, S27 
Nilsson CG, Falconer C & Rezapour M. (2004). Seven-year follow-up of the tension-free 
vaginal tape procedure for treatment of urinary incontinence. Obstet Gynecol, Vol. 
104, pp. 1259–1262 
Nilsson CG, Palva K, Rezapour M, et al. (2008). Eleven years prospective follow-up of the 
tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int 
Urogynecol J Pelvic Floor Dysfunct, Vol. 19, pp. 1043–7 
www.intechopen.com
 
Urinary Incontinence 
 
318 
Nitta M, Tamaki T, Tono K, et al. (2010). Reconstitution of experimental neurogenic bladder 
dysfunction using skeletal muscle-derived multipotent stem cells. Transplantation, 
Vol. 89, pp. 1043–1049 
Novara G, Artibani W. (2007). Myoblasts and fibroblasts in stress urinary incontinence. 
Lancet, Vol. 369, pp. 2139-40  
Novara G, Artibani W, Barber MD, et al. (2010). Updated Systematic Review and Meta-
Analysis of the Comparative Data on Colposuspensions, Pubovaginal Slings, and 
Midurethral Tapes in the Surgical Treatment of Female Stress Urinary 
Incontinence. European Urology, Vol. 58, pp. 218–238 
Nygaard IE and Heit M. (2004). Stress urinary incontinence. Obstet Gynecol, Vol. 104, pp. 607 
Petros P, Ulmsten U. (1993). An integral theory and its method for the diagnosis and 
management of female urinary incontinence. Scand J Urol Nephrol Suppl, Vol. 153, 
pp. 1-93 
Pittenger MF, Mackay AM, Beck SC, et al. (1999). Multilineage potential of adult human 
mesenchymal stem cells. Science, Vol. 284, pp. 143–7 
Prevel CD, Eppley BL, Summerlin DJ, et al. (1995). Small intestinal submucosa: use in repair 
of rodent abdominal wall defects. Ann Plast Surg, Vol. 35, pp. 374–380 
Price N, Dawood R and Jackson SR. (2010). Pelvic floor exercise for urinary incontinence: A 
systematic literature review. Maturitas, Vol. 67, pp. 309–315 
Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 
Vol. 276, pp. 71–4 
Qu-Petersen Z, Deasy B, Jankowski R, et al. (2002). Identification of a novel population of 
muscle stem cells in mice: potential for muscle regeneration. J Cell Biol, Vol. 157, pp. 
851–864 
Rezapour M & Ulmsten U. (2001a): Tension-free vaginal tape (TVT) in women with 
recurrent stress urinary incontinence–a long-term follow-up. Int Urogynecol J Pelvic 
Floor Dysfunct, Vol. 12, pp. S9–S11 
Rezapour M & Ulmsten U. (2001b): Tension free vaginal tape (TVT) in women with mixed 
urinary incontinence–a long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct, 
Vol. 12, pp. S15–18 
Rezapour M, Falconer C & Ulmsten U. (2001c). Tension-free vaginal tape (TVT) in stress 
incontinent women with intrinsic sphincter deficiency (ISD)–a long-term follow-up. 
Int Urogynecol J Pelvic Floor Dysfunct, Vol. 12, pp. S12–14 
Roche R, Festy F, Fritel X. (2010). Stem cells for stress urinary incontinence: The adipose 
promise. J Cell Mol Med, Vol. 14, pp. 135–142 
Rodríguez L, Alfonso Z, Zhang R, et al. (2006). Clonogenic multipotent stem cells in human 
adipose tissue differentiate into functional smooth muscle cells. Proc Natl Acad Sci 
USA, Vol. 103, pp. 12167-72 
Rosch R, Junge K, Hölzl F et al. (2004). How to construct a mesh. In: Schumpelick V, Nyhus 
LM (eds) Meshes: benefits and risks, 179–184, Springer, Berlin Heidelberg New 
York.  
Roumeguere T, Quackels T, Bollens R, et al. (2005). Trans-obturator vaginal tape (TOT) for 
female stress incontinence: one year follow-up in 120 patients. Eur Urol, Vol. 5, pp. 
805–809 
www.intechopen.com
Futuristic Concept in Management  
of Female SUI: Permanent Repair Without Permanent Material 
 
319 
Rutner AB, Levine SR, Schmaelzle JF. (2003). Processed porcine small intestine submucosa 
as a graft material for pubovaginal slings: durability and results. Urology, 62, pp. 
805-809  
Sadek HA, Martin CM, Latif SS, et al. (2009). Bone-marrow-derived side population cells for 
myocardial regeneration. J Cardiovasc Transl Res, Vol. 2, pp. 173–181. 
Santucci RA, Barber TD. (2005). Resorbable extracellular matrix grafts in urologic 
reconstruction. Int Braz J Urol, Vol. 31, pp. 192-203 
Sharma AK, Secrest CL. (2003). Small intestinal submucosa (SIS) graft reconstruction of 
urethra. J Urol, Vol. 169, pp. 101 (Abstract no. 393) 
Stanton SL, Brindley GS, Holmes DM. (1985). Silastic sling for urethral sphincter 
incompetence in women. Br J Obstet Gynaecol, Vol. 92, pp. 747–50 
Seale P, Rudnicki MA. (2000). A new look at the origin, function, and “stem-cell” status of 
muscle satellite cells. Dev Biol, Vol. 218, pp. 115–124 
Strasser H, Marksteiner R, Margreiter E, et al (2007a). Transurethral ultrasonography-guided 
injection of adult autologous stem cells versus transurethral endoscopic injection of 
collagen in treatment of urinary incontinence. World J Urol, Vol. 25, pp. 385–92 
Strasser H, Marksteiner R, Margreiter E, et al. (2007b). Autologous myoblasts and fibroblasts 
versus collagen for treatment of stress urinary incontinence in women: a 
randomized controlled trial. Lancet, Vol. 369, pp. 2179-86 
Strem B, Hicok K, Zhu M, et al. (2005). Multipotential differentiation of adipose tissue-
derived stem cells. Keio J Med, Vol. 54, pp. 132-41 
Sweat SD, Itano NB, Clemens JQ, et al. (2002). Polypropylene mesh tape for stress urinary 
incontinence: complications of urethral erosion and outlet obstruction. J Urol, Vol. 
168, pp. 144–7 
Ulmsten U, Henriksson L, Johnson P, et al. (1996). An ambulatory surgical procedure under 
local anesthesia for treatment of female urinary incontinence. Int Urogynecol J, Vol. 
7, pp. 81–86 
Villet R, Atallah D, Cotelle-Bernede O, et al. (2002). Treatment of stress urinary incontinence 
with tension-free vaginal tape (TVT). Mid-term results of a prospective study of 124 
cases [in French]. Prog Urol, Vol. 12, pp. 70–76 
Waltregny D, Gaspar Y, Reul O, et al. (2008). for the treatment of female stress urinary 
incontinence: results of a prospective study after a 3-year minimum follow-up. Eur 
Urol, Vol. 53, pp. 401–408 
Ward KL & Hilton P. (2004). The United Kingdom and Ireland Tension- Free Vaginal Tape 
Trial Group: A prospective multicenter randomized trial of tension-free vaginal 
tape and colposuspension for primary urodynamic stress incontinence: 2-year 
follow-up. Am J Obstet Gynecol, Vol. 190, pp. 324–331 
Ward KL & Hilton P. (2008). The United Kingdom and Ireland Tension- Free Vaginal Tape 
Trial Group: Tension-free vaginal tape versus colposuspension for primary 
urodynamic stress incontinence: 5-year follow-up. BJOG, Vol. 15, pp. 226-233 
Wiedemann A, Otto M. (2004). Small intestinal submucosa for pubourethral sling 
suspension for the treatment of stress incontinence: first histopathological results in 
humans. J Urol, Vol. 172, pp. 215-218 
Winters JC, Fitzgrerald MP and Barber MD. (2006). The use of synthetic mesh in female 
reconstructive surgery. BJU International, Vol. 98 (suppl 1), pp. 70–76  
www.intechopen.com
 
Urinary Incontinence 
 
320 
Yamamoto T, Gotoh M, Hattori R, et al. (2010). Periurethral injection of autologous adipose-
derived stem cells for the treatment of stress urinary incontinence in patients 
undergoing radical prostatectomy: report of initial two cases. Int J Urol, Vol. 17, pp. 
75–82 (Retraction in Int J Urol, 2010, Vol. 17, pp. 896) 
Yokoyama T, Yoshimura N, Dhir R, et al. (2001a). Persistence and survival of autologous 
muscle derived cells versus bovine collagen as potential treatment of stress urinary 
incontinence. J Urol, Vol. 165, pp. 271–6 
Yokoyama T, Pruchnic R, Lee JY, et al. (2001b). Autologous primary muscle-derived cells 
transfer into the lower urinary tract. Tissue Eng, Vol. 7, pp. 395–404 
Zhang Y, Luo H, Zhang Z, et al. (2010). A nerve graft constructed with xenogeneic acellular 
nerve matrix and autologous adipose-derived mesenchymal stem cells. Biomaterials, 
Vol. 31, pp. 5312–532416.  
www.intechopen.com
Urinary Incontinence
Edited by Mr. Ammar Alhasso
ISBN 978-953-51-0484-1
Hard cover, 324 pages
Publisher InTech
Published online 04, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Management strategies are framed within a multidisciplinary team structure and as such a range of specialists
ranging from psychologists, specialist nurses, gynaecologists and urologists author the chapters. There are
some novel methods outlined by the authors with their clinical application and utility described in detail, along
with exhaustive research on epidemiology, which is particularly relevant in planning for the future.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yasser Farahat and Ali Abdel Raheem (2012). Futuristic Concept in Management of Female SUI: Permanent
Repair Without Permanent Material, Urinary Incontinence, Mr. Ammar Alhasso (Ed.), ISBN: 978-953-51-0484-
1, InTech, Available from: http://www.intechopen.com/books/urinary-incontinence/futuristic-concept-in-
management-of-female-sui-permanent-repair-without-permanent-material
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
